Administration of AP1903 does not adversely affect T-cell immune recovery. Counts of circulating T cells in 6 patients who did not receive AP1903 (A) and 3 patients who received AP1903 and had follow-up more than 6 weeks (B). Arrows and red symbols indicate the administration of AP1903 and the time when patients went off-study, respectively. Counts of specific T-cell subsets in patients who did not receive AP1903 (C) and those who received AP1903 (D). *Data from 1 patient. (E) T-cell receptor Vβ receptor repertoire in untreated patients (upper) or in those who received AP1903 (lower); repertoires of CD3⁺CD19⁺ and CD3⁺CD19⁻ T cells are shown. The analysis was performed in samples collected at a median of 7 months (range, 2-12 months) after iC9-T cell infusion for patients who had received AP1903 and a median of 6 months (range, 4-12 months) for patients who did not receive AP1903.